{
  "paper_metadata": {
    "pmid": "31853709",
    "title": "MAIN TEXT",
    "extraction_summary": "The paper discusses the impact of inotersen on quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy. It mentions the Val30Met mutation in the TTR gene but does not provide detailed variant-specific data or penetrance information."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": "Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 165,
        "demographics": "Patients with hereditary transthyretin amyloidosis with polyneuropathy, mean age 59.6 years, 29.2% female",
        "phenotype": "polyneuropathy, cardiomyopathy"
      },
      "penetrance_data": {
        "total_carriers_observed": null,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "The paper does not provide specific functional data for the Val30Met variant.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "medium",
      "source_location": "Methods, paragraph 3",
      "additional_notes": "The Val30Met mutation is mentioned as a stratification factor in the study.",
      "key_quotes": [
        "Patients were randomized to receive 300 mg inotersen or placebo in a 2:1 ratio within each of three strata: presence/absence of previous treatment with tafamidis and/or diflunisal; Stage 1 (ambulatory without assistance) or Stage 2 (ambulatory with assistance) neurologic disease severity, according to Coutinho et al.\u2019s staging; and Val30Met mutation or non-Val30Met mutation."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Baseline patient characteristics in the NEURO-TTR trial full analysis set (n\u2009=\u2009165)",
      "variants_extracted": 0
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [
      "The paper does not provide detailed penetrance data or individual-level records for the Val30Met variant."
    ],
    "notes": "The extraction focused on the Val30Met mutation as it was the only TTR variant mentioned. No detailed penetrance or individual-level data were available."
  }
}